+

PE20181288A1 - Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer - Google Patents

Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer

Info

Publication number
PE20181288A1
PE20181288A1 PE2018000611A PE2018000611A PE20181288A1 PE 20181288 A1 PE20181288 A1 PE 20181288A1 PE 2018000611 A PE2018000611 A PE 2018000611A PE 2018000611 A PE2018000611 A PE 2018000611A PE 20181288 A1 PE20181288 A1 PE 20181288A1
Authority
PE
Peru
Prior art keywords
cancer
treatment
alkyl
derivatives used
dihydroimidazopyrazinone
Prior art date
Application number
PE2018000611A
Other languages
English (en)
Inventor
Richard Andrew Ward
Clifford David Jones
Steven Swallow
Mark Andrew Graham
Andrew Hornby Dobson
James Francis Mccabe
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20181288A1 publication Critical patent/PE20181288A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se refiere a un compuesto derivado de dihidroimidazopirazinona de formula (I), donde R1 es H, alquilo C1-3, entre otros; R2 es fenilo, piridinilo o pirimidinilo, donde piridinilo o pirimidinilo estan opcionalmente sustituidos en 1 atomo de carbono en el anillo por un sustituyente que consiste en alquilo C1-C3, difluorometilo, trifluorometilo; R3 es H, alquilo C1-C3, entre otros. Dichos compuestos utiles en el tratamiento del cancer tales como cancer de pancreas, colorrectal, entre otros
PE2018000611A 2015-11-09 2016-11-08 Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer PE20181288A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562252726P 2015-11-09 2015-11-09
US201662401351P 2016-09-29 2016-09-29

Publications (1)

Publication Number Publication Date
PE20181288A1 true PE20181288A1 (es) 2018-08-07

Family

ID=57241113

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000611A PE20181288A1 (es) 2015-11-09 2016-11-08 Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer

Country Status (36)

Country Link
US (2) US9902731B2 (es)
EP (1) EP3374359B1 (es)
JP (1) JP6877423B2 (es)
KR (1) KR20180074788A (es)
CN (1) CN108349983B (es)
AU (1) AU2016351813B2 (es)
BR (1) BR112018008397B1 (es)
CA (1) CA3003549A1 (es)
CL (1) CL2018001226A1 (es)
CO (1) CO2018004857A2 (es)
CR (1) CR20180316A (es)
CY (1) CY1123627T1 (es)
DK (1) DK3374359T3 (es)
EA (1) EA038028B1 (es)
ES (1) ES2780650T3 (es)
HK (1) HK1256283A1 (es)
HR (1) HRP20200342T1 (es)
IL (1) IL258953A (es)
LT (1) LT3374359T (es)
ME (1) ME03770B (es)
MX (1) MX376639B (es)
MY (1) MY197626A (es)
NI (1) NI201800058A (es)
PE (1) PE20181288A1 (es)
PH (1) PH12018500987A1 (es)
PL (1) PL3374359T3 (es)
PT (1) PT3374359T (es)
RS (1) RS60155B1 (es)
SG (1) SG11201803066VA (es)
SI (1) SI3374359T1 (es)
SM (1) SMT202000152T1 (es)
SV (1) SV2018005687A (es)
TN (1) TN2018000119A1 (es)
TW (1) TWI730012B (es)
WO (1) WO2017080979A1 (es)
ZA (1) ZA201803742B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3001799A1 (en) 2015-10-21 2017-04-27 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
EP3374359B1 (en) * 2015-11-09 2020-01-08 AstraZeneca AB Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
WO2020073862A1 (zh) * 2018-10-10 2020-04-16 深圳市塔吉瑞生物医药有限公司 一种二氢咪唑并吡嗪酮化合物及包含该化合物的组合物及其用途
CA3134405A1 (en) 2019-03-28 2020-10-01 Jiangsu Hengrui Medicine Co., Ltd. Thienoheterocyclic derivative, preparation method therefor and medical use thereof
JP2022534224A (ja) 2019-05-24 2022-07-28 江蘇恒瑞医薬股▲ふん▼有限公司 置換縮合二環式誘導体、その調製方法、および医薬におけるその適用
BR112021024546A2 (pt) 2019-06-06 2022-02-08 Hutchison Medipharma Ltd Compostos tricíclicos e uso dos mesmos
AR120685A1 (es) 2019-12-05 2022-03-09 Astrazeneca Ab Proceso e intermediarios para la producción de la fórmula (1)
CN114829365B (zh) * 2019-12-06 2023-04-25 南京明德新药研发有限公司 作为erk抑制剂的噻唑并内酰胺类化合物及其应用
KR20230079120A (ko) 2020-09-29 2023-06-05 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 피롤로 헤테로고리계 유도체의 결정형 및 이의 제조 방법
AR126166A1 (es) * 2021-06-18 2023-09-27 Antengene Discovery Ltd Combinación de un inhibidor de erk y un inhibidor de kras y usos de estos
WO2022268065A1 (en) * 2021-06-22 2022-12-29 Fochon Biosciences, Ltd. Compounds as erk inhibitors
AU2022320304A1 (en) 2021-07-27 2024-02-29 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
US20250129090A1 (en) 2021-11-04 2025-04-24 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing
WO2023212231A1 (en) 2022-04-27 2023-11-02 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing
EP4522623A1 (en) 2022-05-12 2025-03-19 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing
WO2024006971A2 (en) * 2022-07-01 2024-01-04 The Scripps Research Institute Antimalarial compounds

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
AU2003278377A1 (en) * 2002-11-06 2004-06-07 Merck Sharp And Dohme Limited Imidazopyrazinones and imidazotriazinones derivates as gaba-a receptor anxiolytic
GB0520958D0 (en) 2005-10-14 2005-11-23 Cyclacel Ltd Compound
EP2132178B1 (en) * 2006-12-20 2015-08-19 Merck Sharp & Dohme Corp. Jnk inhibitors
WO2012085038A1 (en) * 2010-12-22 2012-06-28 Janssen Pharmaceutica Nv 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)
US9643970B2 (en) * 2011-10-10 2017-05-09 H. Lundbeck A/S Substituted imidazo [1,5-a]pyrazines as PDE9 inhibitors
JP2013166727A (ja) * 2012-02-16 2013-08-29 Dainippon Sumitomo Pharma Co Ltd ジヒドロイミダゾピラジノン誘導体
RS57097B1 (sr) 2012-03-01 2018-06-29 Array Biopharma Inc Inhibitori serinske/treoninske kinaze
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
KR102359759B1 (ko) * 2013-12-06 2022-02-09 제넨테크, 인크. 세린/트레오닌 키나제 저해제
CA2934709C (en) 2013-12-30 2022-08-30 Array Biopharma Inc. Serine/threonine kinase inhibitors
CN105848723B (zh) 2013-12-30 2019-08-02 基因泰克公司 丝氨酸/苏氨酸激酶抑制剂
BR122020014933B8 (pt) 2014-04-09 2022-12-13 Genentech Inc Compostos, composições farmacêuticas, benzenossulfonatos, forma a de ácido p-toluenossulfônico, forma b de ácido p-toluenssulfônico, forma i do ácido naftalenodissulfônico e forma ii do ácido naftalendissulfônico
US10412619B2 (en) * 2014-11-14 2019-09-10 Qualcomm Incorporated Buffer status report for eDCS
WO2016162325A1 (en) * 2015-04-07 2016-10-13 Astrazeneca Ab Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1 (2h)-one derivatives as kinase inhibitors
WO2016192063A1 (en) 2015-06-03 2016-12-08 Changzhou Jiekai Pharmatech Co. Ltd Heterocyclic compounds as erk inhibitors
CA2987963C (en) 2015-06-03 2023-01-24 Js Innopharm (Shanghai) Ltd. Heterocyclic compounds for treating psoriasis
EP3374359B1 (en) * 2015-11-09 2020-01-08 AstraZeneca AB Dihydroimidazopyrazinone derivatives useful in the treatment of cancer

Also Published As

Publication number Publication date
MY197626A (en) 2023-06-29
CL2018001226A1 (es) 2018-10-05
MX376639B (es) 2025-03-07
RS60155B1 (sr) 2020-05-29
JP2019503337A (ja) 2019-02-07
NI201800058A (es) 2018-10-18
ME03770B (me) 2021-04-20
SV2018005687A (es) 2018-07-20
CR20180316A (es) 2018-10-05
TN2018000119A1 (en) 2019-10-04
KR20180074788A (ko) 2018-07-03
US10202391B2 (en) 2019-02-12
AU2016351813A1 (en) 2018-06-21
EP3374359B1 (en) 2020-01-08
WO2017080979A1 (en) 2017-05-18
SI3374359T1 (sl) 2020-04-30
PL3374359T3 (pl) 2020-06-29
ES2780650T3 (es) 2020-08-26
PH12018500987A1 (en) 2019-01-28
US20170204100A1 (en) 2017-07-20
SMT202000152T1 (it) 2020-05-08
CO2018004857A2 (es) 2018-07-19
CN108349983A (zh) 2018-07-31
EA038028B1 (ru) 2021-06-24
BR112018008397B1 (pt) 2023-12-12
ZA201803742B (en) 2020-08-26
EP3374359A1 (en) 2018-09-19
CN108349983B (zh) 2021-02-26
US20180237443A1 (en) 2018-08-23
CY1123627T1 (el) 2022-03-24
PT3374359T (pt) 2020-03-27
HRP20200342T1 (hr) 2020-06-12
LT3374359T (lt) 2020-03-25
CA3003549A1 (en) 2017-05-18
US9902731B2 (en) 2018-02-27
EA201891063A1 (ru) 2018-12-28
TW201728586A (zh) 2017-08-16
IL258953A (en) 2018-06-28
JP6877423B2 (ja) 2021-05-26
HK1256283A1 (zh) 2019-09-20
SG11201803066VA (en) 2018-05-30
MX2018005725A (es) 2018-08-14
AU2016351813B2 (en) 2019-05-30
TWI730012B (zh) 2021-06-11
DK3374359T3 (da) 2020-03-30
BR112018008397A2 (pt) 2018-10-23

Similar Documents

Publication Publication Date Title
PE20181288A1 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
CU24572B1 (es) Compuestos derivados de 1,2,4-triazolonas 2,4,5-trisustituidas
PH12017501016B1 (en) Triazolopyrimidine compounds and uses thereof
CY1120188T1 (el) ΠΑΡΑΓΩΓΑ ΝΑΦΘΥΡΙΔΙΝΗΣ ΧΡΗΣΙΜΑ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ ΙΝΤΕΓΚΡΙΝΗΣ αvβ6
EA033294B1 (ru) Пиридазиноновые гербициды
PE20180024A1 (es) Triazolopirazinonas como inhibidores de pde1
PE20181145A1 (es) Compuestos de piridina
PH12016501941A1 (en) Use of heterocyclic compounds for controlling nematodes
MD20160095A2 (ro) Derivaţi de pirimidiniloxi-benzen utilizaţi ca erbicide
MX367897B (es) Derivados de piridazinona macrociclicos.
MX375030B (es) Compuestos de n,6-bis(aril o heteroaril)-1,3,5-triazin-2,4-diamina como inhibidores de idh2 mutantes para el tratamiento de cancer.
EA201691472A1 (ru) Конденсированные пиримидины в качестве ингибиторов комплекса p97
MX388321B (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
TN2018000020A1 (en) Colony stimulating factor-1 receptor (csf-1r) inhibitors.
PE20200387A1 (es) Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer
MX2015015786A (es) Compuestos de n-(tetrazol-5-il)- y n-(triazol-5-il) arilcarboxamida sustituidos y su uso como herbicidas.
PH12015502611A1 (en) Heterocyclic compounds as hedgehog signaling pathway inhibitors
MX2017000594A (es) Derivados de bis(aril) catecol como herbicidas.
PH12019500839A1 (en) Therapeutic compounds and methods of use thereof
MA38884A1 (fr) Composé de triazolopyridine, compositions et procédés d'utilisation associés
EA201690227A1 (ru) Азаиндольные соединения, их получение и способы их применения
EP2602254A4 (en) HETEROCYCLIC CONNECTION
PH12015502462A1 (en) Imidazo-triazine derivatives as pde10 inhibitors
AR106958A1 (es) Derivados de tetrahidrotriazolopirimidina útiles como inhibidores de hne
MX390752B (es) Compuesto heterociclico.
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载